secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001193125-25-177941
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta Q3 net loss $18.3M ($0.85/sh); RSV topline data due Sept
---------------------------------------------------------------

- Revenue of $18.3M from AbbVie royalties; net loss narrowed vs $22.7M Q3 2024.
- Cash & securities $204.1M; cash runway into fiscal 2028.
- RSVHR Phase 2b fully enrolled (186 patients); topline data expected September.
- IND-enabling studies ongoing for oral KIT inhibitor EPS-1421; STAT6 candidate selection in 2H 2025.
- AbbVie received FDA approval for expanded MAVYRET indication in acute HCV.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000119312525177941/0001193125-25-177941-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000119312525177941/enta-20250811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-177941

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer